Prerpints.org logo
Preprint
Article

This version is not peer-reviewed.

LncRNA MYU Facilitates Angiogenesis in HUVECs under Hypoxia by Functioning as a ceRNA for miR-23a-3p

Submitted:

19 June 2024

Posted:

20 June 2024

You are already at the latest version

Abstract
Background: Angiogenesis is essential for various physiological and pathological processes, such as embryonic development and cancer cell proliferation, migration, and invasion. Long noncoding RNAs (lncRNAs) play pivotal roles in normal homeostasis and disease processes by regulating gene expression through various mechanisms, including as competing endogenous RNAs (ceRNAs) of target microRNAs (miRNAs). The lncRNA MYU is known to promote prostate cancer proliferation via the miR-184/c-Myc regulatory axis, and to be upregulated in vascular endothelial cells under hypoxic conditions, which often occurs in solid tumors. In the present study, we investigated whether MYU might affect cancer growth by regulating angiogenesis in vascular endothelial cells under hypoxia. Methods: The expression of MYU-regulated miR-23a-3p and interleukin-8 (IL-8) in HUVEC cell lines was examined using qRT-PCR. CCK-8 assay, EdU assay, Wound-healing assay and Tube-formation assay were used to assess the effect of MYU on cell proliferation, migration and tube formation of HUVEC cells in vitro. Dual-luciferase reporter assay was performed to examine the effect of miR-23a-3p on MYU and IL-8 expression. Results: We found that overexpression of MYU and knockdown of miR-23a-3p in human umbilical vein endothelial cells (HUVECs) under hypoxia promoted cell proliferation, migration, and tube formation. Mechanistically, MYU was shown to bind competitively to miR-23a-3p, thereby preventing miR-23a-3p binding to the 3′ untranslated region of IL-8 mRNA. In turn, increased production of pro-angiogenic IL-8 promoted HUVEC proliferation, migration, and tube formation under hypoxia. Conclusion: This study identified a new role for lncRNA MYU as a ceRNA for miR-23a-3p, and uncovered a novel MYU–miR-23a-3p–IL-8 regulatory axis for angiogenesis. MYU and/or miR-23a-3p may thus represent new targets for the treatment of hypoxia-related diseases by promoting angiogenesis.
Keywords: 
HUVEC
;  
MYU
;  
miR-23a-3p
;  
IL-8
;  
angiogenesis
Subject: 
Biology and Life Sciences  -   Cell and Developmental Biology

Introduction

Angiogenesis is the process by which new capillaries are formed from pre-existing blood vessels through matrix remodeling and endothelial cell budding, proliferation, and migration [1,2,3]. As the primary conduits for oxygen and nutrient supply to tissues and the distribution of immune cells to sites of damage and infection, blood vessels play essential roles in the maintenance of normal tissue growth and physiology in vertebrates. Angiogenesis is thus involved in many physiological and pathological processes, including embryonic development[4], Menstrual Cycle[5], placental development[6], retinal health[7], wound healing[8], and tumor vascular growth[9]. Angiogenesis is regulated by a balance between inducing factors, which include vascular endothelial growth factor (VEGF)[10], angiopoietin[11], and FGF[12], and inhibiting factors, such as arresten[13], endostatin[14], angiostatin[15], and MMP[16]. Interactions between these factors are important for the regulation of angiogenesis, and an imbalance between them is responsible for the abnormal growth of microvessels in many diseases[17]. Although anti-angiogenic agents, such as antibodies that target VEGF and its associated pathways, are currently used for various clinical applications, they have shown limited benefit in many conditions, and there is a continuing need to develop additional drugs that can promote or inhibit angiogenesis.
Long noncoding RNAs (lncRNAs), usually defined as RNAs >200 nucleotides in length that lack protein-coding potential, are increasingly recognized for their important roles in many biological processes. To date, the functions of a small subset of the thousands of lncRNAs in the human genome have been characterized, and multiple mechanisms of action have been identified. Firstly, lncRNAs act as signal molecules and are able to mark the space, time, developmental stage, and expression of gene regulation. Secondly, lncRNAs can act as decoy molecules to recruit other RNA-binding proteins and to regulate RNAs away from their functional sites. A further example of decoys is lncRNA decoy for miRNA target sites. Thirdly, lncRNAs can act as guide molecules, bind proteins or bind specific regions of DNA, and guide protein-RNA complexes to localize to the site to be determined to play a guiding role. Finally, lncRNAs can function as scaffolds for complexes that bind multiple substrates simultaneously[18]. Notably, it has been established that some lncRNAs can regulate angiogenesis under hypoxic conditions; these include H19[19], MALAT1[20], GATA6-AS[21], and MEG3[22,23], which are regulated by hypoxia in vascular endothelial cells. Recently, a new mechanism of action for lncRNAs has been described; namely, as competitive endogenous RNAs (ceRNAs). ceRNAs promote mRNA stability and/or translation by binding to microRNA (miRNAs), thereby acting as molecular sponges that block binding of miRNAs to their target mRNAs. For instance, in human umbilical vein endothelial cells (HUVECs) under hypoxia, lncRNA HIF1A-AS2 promotes upregulation of the key hypoxia-related transcription factor hypoxia-inducible factor-1α (HIF-1α) by binding to miR-153-3p, thereby promoting angiogenesis[24]. Conversely, loss of function of lncRNA UCA1 causes upregulation of miR-195, which leads to downregulation of components of the MEK/ERK and mTOR signaling pathways and CCND1 expression, thus inhibiting the growth of microvascular endothelial cells and vessel formation[25]. LncRNA NEAT1 promotes endothelial cell survival and angiogenesis by binding to miR-377 and promoting the expression of SIRT1, VEGFA, and BCL-XL[26]. LINC01693 acts as a ceRNA of miR-302d and promotes angiogenesis in HUVECs by counteracting miR-302d-mediated inhibition of CXCL12[27]. In glioma vascular endothelial cells, overexpression of the lncRNA PVT1 enhances expression of the autophagy proteins ATG7 and Beclin1 by targeting miR-186, and the subsequent induction of protective autophagy promotes tumor cell proliferation, migration, and angiogenesis [28]. MEG3 also plays an important role in the proliferation and angiogenesis of vascular endothelial cells by acting as a ceRNA and negatively regulating miR-9[29].
A recent study showed that the lncRNA MYU is upregulated by the Wnt/c-Myc signaling pathway, and promotes cell cycle progression by interacting with the RNA-binding protein hnRNP-K and stabilizing CDK6 expression[30]. Interestingly, MYU acts as a tumor promoter in colorectal cancer (CRC) but as a tumor suppressor in gastric cancer[31]. MYU, a product of the antisense strand of the VPS9D1 gene, was among many functional lncRNAs shown to be associated with HUVEC angiogenesis under hypoxic conditions[32]. In that study, Moreau et al. investigated the lncRNA profiles of hypoxic human primary endothelial cells using Global Nuclear Run-On Sequencing (GRO-Seq), and they identified 1763 differentially expressed lncRNAs, of which 544 were upregulated and 350 were downregulated (>2-fold) under hypoxia compared with normoxia. Most of these differentially expressed lncRNAs have yet to be functionally validated. In the present study, we selected MYU for further investigation of its mechanism of action using HUVECs, which respond to pro-angiogenic factors such as VEGF, HIF-1α, and IL-8 and are a widely used model for studying the angiogenic process. We investigated the role of MYU in regulating HUVEC proliferation, migration, invasion, and angiogenesis under hypoxic conditions, and identified MYU as a ceRNA for miR-23b-3p, which, in turn, controls IL-8 expression.

Materials and Methods

TCGA database analysis

The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/repository) mainly includes clinical data, genomic variations, mRNA expression, miRNA expression, methylation and other data of various human cancers, which is a very important data source for cancer researchers. First we downloaded HTSeq-FPKM data of 22 common cancers by TCGA. The expression of the MYU gene for each sample of the 22 common cancers was then extracted using the R language and subjected to statistical analysis.

In vitro translation analysis

The constructed MYU overexpression plasmid was transfected into the HeLa cell line and cultured in a 5% CO2 incubator for 48 h. Total protein was extracted using Cell lysis buffer for Western and IP (Beyotime, Shanghai, China), and protein concentration was determined by Enhanced BCA Protein Assay Kit (Beyotime, Shanghai, China), followed by constant voltage electrophoresis at 120 V for 2 h using NUPAGE 10% BT GEL 1.0MM 10W 10 PER BOX (Invitrogen, Grand Island, NY, USA), then staining was conducted by using the Coomassie brilliant blue rapid staining solution (Solarbio, Beijing, China), and photographs were taken after the end of staining.

Cell culture and transfection

HUVECs were obtained from Institute of Cardiovascular Diseases, University of South China (Hengyang, Hunan, China) and cultured in DMEM (Hyclone, Logan, UT, USA) containing 10% fetal bovine serum (FBS; GIBCO, Grand Island, NY, USA), penicillin, and streptomycin (×100). The cells were maintained at 37°C in a 5% CO2 atmosphere, and the medium was changed every 2 to 3 days. Hypoxia was induced by placing cells in a 2.5 L anaerobic jar (MGC, Tokyo, Japan) with an AnaeroPack-Anaero (MGC, Tokyo, Japan), which generates hypoxic conditions (defined as <1% O2, 5% CO2, 94% N2) within 1 h. Normoxia was defined as 5% CO2 in air.
Cells were transfected with a miR-23a-3p mimic, a control negative control sequence (NC), or a miRNA inhibitor (RIBOBIO, Guangzhou, Guangdong, China) using HiPerFect transfection reagent (Qiagen, Dusseldorf, North Rhine-Westphallen, Germany). Overexpression plasmids with or without the miRNA mimic were transfected into cells using Lipofectamine3000 (Invitrogen, Grand Island, NY, USA).

Plasmid construction

The MYU overexpression plasmid was constructed by cloning the complete sequence of MYU into pcDNA3.1 (+) vector via KpnI and EcoRI sites. For the luciferase reporter assays, MYU sequences containing either the wild-type putative binding site for miR-23a-3p (MYU-WT) or one in which the putative binding site was mutated (MYU-MUT) were cloned into pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega). Additional pmirGLO plasmids were constructed in which luciferase expression was driven by the wild-type 3′ untranslated region (3′UTR) of IL-8 (IL-8-WT) or one in which the putative miR-23a-3p binding site was mutated (IL-8-MUT).

Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)

Total RNA was extracted from cells using TRIzol reagent (TaKaRa, Tokyo, Japan) according to the manufacturer’s instructions. Samples of 1 μg RNA were reverse-transcribed using a PrimeScript RT Reagent Kit with gDNA Eraser (Perfect Real Time; TaKaRa), and aliquots of cDNA were amplified by qPCR using TB Green Premix Ex Taq II (TliRNaseH Plus; TaKaRa) and a Bio-Rad CFX Connect™ quantitative fluorescence PCR detection system according to the manufacturer’s instructions. The reaction conditions were: 95°C for 30 s followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was amplified as an internal control. Primer sequences for qPCR are listed in Table 1.

Isolation of nuclear and cytoplasmic RNA

Nuclear and cytoplasmic RNA fractions were isolated from HUVEC cells and purified using a Nuclei EZ Prep kit (Sigma, San Francisco, CA, USA). Nuclei were stained using trypan blue solution and the purity of the final nuclei was determined by microscopy.

Dual-luciferase reporter assay

Cells were plated in 48-well plates and transfected with the appropriate pmirGlo vector and control or miRNA mimic using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions. Luciferase activity was measured at ~36–48 h after transfection using a Dual-Luciferase Assay kit (Beyotime, Shanghai, China) according to the manufacturer’s manual.

CCK-8 assay

HUVECs were seeded into 96-well plates and subjected to the indicated treatments (n = 5). At baseline (0 h) and after 6, 12, 24, and 48 h incubation, 10 μL of CCK-8 reagent (Beyotime) was added to each well and the incubation was continued for 2 h. The absorbance at 450 nm was then read in a microplate reader (BioTek, Burlington, VT, USA).

EdU assay

HUVECs were seeded into 96-well plates, subjected to the indicated treatments, and stained using an Cell-Light EdU Apollo567 In Vitro Kit (RIBOBIO) according to the manufacturer’s manual. Cells were examined using an inverted fluorescence microscope (Leica, Wetzlar, Hesse, Germany). Images of whole cells and nuclei were captured and the proportion of replicating cells was calculated.

Wound-healing assay

HUVECs were seeded into 12-well plates and grown to confluency. A wound was inflicted by passing a 10 μL pipette tip across the monolayer. The non-adherent cells were removed, and the cells were photographed, incubated at 37°C for 24 h, and photographed again. Wound closure was calculated from the photographs images captured at 0 and 24 h. Experiments were repeated at least three times.

Tube-formation assay

Matrigel (Corning, Corning, NY, USA) was added to 24-well plates and allowed to gel at 37°C in a 5% CO2 atmosphere for 30–60 min. HUVECs (1.2 × 105 cells/500 μL) were added to the wells and the plates were incubated at 37°C under hypoxic conditions. Tube formation was evaluated using an inverted microscope (Leica). Image-Pro Plus 5.0 (Media Cybernetics, Rockville, MD, USA) software was used to analyze the tube lengths and branches in 10 randomly selected visual fields.

Statistical analysis

Data are expressed as the mean ± standard deviation (SD) of triplicates unless noted. Differences between two groups were evaluated by two-tailed Student's t-test and differences among multiple groups were evaluated by two-way ANOVA. A two-tailed p value <0.05 was considered significant. All analyses were performed using Prism 8.0 (GraphPad Software, San Diego, CA, USA).

Results

1. Expression pattern of MYU and upregulation under hypoxia in vitro

To determine whether MYU (VPS9D1-AS1) might be involved in angiogenesis during cancer, we examined its expression levels in different tumor tissues compared with the corresponding normal tissues by interrogating RNA-seq datasets of 22 common malignancies from The Cancer Genome Atlas database. Expression of MYU was higher in tumor tissues than in normal tissues for all 22 malignancies, and the difference reached significance for bladder urothelial carcinoma (p = 0.0011), breast invasive carcinoma (p = 0.0008), colon adenocarcinoma (p < 0.0001), esophageal carcinoma (p = 0.0028), kidney renal clear cell carcinoma (p < 0.0001), liver hepatocellular carcinoma (p = 0.0039), lung adenocarcinoma (p < 0.0001), lung squamous cell carcinoma (p < 0.0001), prostate adenocarcinoma (p < 0.0001), stomach adenocarcinoma (p < 0.0001), and uterine corpus endometrial carcinoma (p = 0.0002) (Figure 1A). Because hypoxia-stimulated angiogenesis is a common feature of many solid tumors, we speculated that the upregulation in MYU may be associated with induction of angiogenesis under hypoxic conditions.
Using the UCSC Genome Browser, we determined that the MYU sequence was highly conserved across species (Figure 1B). PhyloCSF analysis indicated the possibility that MYU may have potential protein-coding capacity (Figure 1B). However, the results of in vitro translation experiments showed that no additional protein bands were identified in HeLa cell extracts in the presence of MYU compared with controls (Figure 1C), indicating that MYU transcripts are unlikely to be protein coding. To determine the subcellular localization of MYU, we isolated nuclei (Figure 1D) and cytoplasmic fractions from HUVECs and performed qRT-PCR analysis of MYU. This analysis revealed that most of the MYU transcripts were localized in the nucleus (Figure 1E). We next investigated whether MYU expression was altered in HUVECs under hypoxic conditions (<0.1% O2), which might support a potential role for this lncRNA in promoting tumor angiogenesis. Notably, while MYU expression was progressively downregulated in cells cultured in hypoxia conditions, MYU levels were essentially maintained for up to 48 h under normoxic (Figure 1F). This finding is consistent with the results of Moreau et al. [32] showing downregulation of MYU in HUVECs in response to hypoxia.

2. HUVEC proliferation, migration, and angiogenesis under hypoxia are promoted by MYU

To investigate the role of MYU in angiogenesis under hypoxic conditions, we transfected HUVECs with an MYU overexpression vector or empty vector (control) and confirmed that expression of MYU was increased (~65-fold) by qRT-PCR (Figure 2A). Next, we analyzed expression of the angiogenesis-related factors VEGF, HIF-1α, and IL-8 in control and MYU-overexpressing HUVECs under hypoxia. We observed that expression of IL-8 mRNA, but not VEGF or HIF-1α mRNA, was significantly increased by MYU overexpression (Figure 2B, p < 0.01). Evaluation of cell proliferation under hypoxia using CCK-8 and EdU proliferation assays indicated that MYU overexpression also increased HUVEC cell proliferation compared with control cells (p < 0.05 and p < 0.01, respectively; Figure 2C–E). Similarly, migration of HUVECs under hypoxia was promoted by MYU overexpression, as measured using wound-healing assays (Figure 2F, G, p < 0.01). Finally, we performed tube-formation assays of HUVECs in Matrigel-coated wells and found that MYU overexpression significantly promoted not only tube formation but also branching under hypoxic conditions (Figure 2H–J, p < 0.01). These results indicated that MYU overexpression can promote HUVEC proliferation, migration, and angiogenesis during hypoxia.

3. MYU overexpression downregulates miR-23a-3p in HUVECs under hypoxia

We next probed the pro-angiogenic mechanism of action of MYU in HUVECs by RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid) for miRNAs with sequences complementary to MYU. We found that MYU contains a putative binding site for miR-23a-3p (Figure 3A). qRT-PCR analysis of HUVECs indicated that miR-23a-3p expression was significantly reduced in MYU-overexpressing HUVECs compared with control HUVECs under hypoxia (Figure 3B, p < 0.05), which supported a potential interaction between the two RNAs. To confirm this, we performed luciferase reporter assays in which HUVECs were transfected with an MYU mimic together with either a luciferase plasmid containing the WT-MYU sequence or MUT-MYU sequence in which the putative miR-23a-3p binding site was disrupted (Figure 3A). Notably, luciferase activity was significantly reduced in cells overexpressing the miR-23a-3p mimic together with the MYU-WT plasmid compared with cells expressing the MYU-MUT plasmid (p < 0.01, Figure 3C). These data demonstrated that MYU contains functional miR-23a-3p binding site.

4. HUVEC proliferation, migration, and angiogenesis under hypoxia is inhibited by miR-23a-3p overexpression

miR-23a-3p has been reported to induce angiogenesis in tumor cells under hypoxia, but this has not been demonstrated in HUVECs. Therefore, to investigate the role of miR-23a-3p in HUVEC angiogenesis, we transfected HUVECs with a miR-23a-3p mimic, a negative control sequence (NC), or a miR-23a-3p inhibitor, and incubated the cells under hypoxic conditions. qRT-PCR analysis of VEGF, HIF-1α, and IL-8 revealed that IL-8 mRNA levels were downregulated modestly but significantly by the miR-23a-3p mimic compared with NC (p < 0.05) and were upregulated significantly by the miR-23a-3p inhibitor compared with NC (Figure 4A, p < 0.01). Interestingly, VEGFA mRNA levels were unaffected by modulation of miR-23a-3p expression, whereas HIF-1α was upregulated by the miR-23a-3p inhibitor but unaffected by the mimic (Figure 4A). These results suggested that, like MYU, miR-23a-3p regulates the expression of angiogenic factors in HUVECs exposed to hypoxia. In addition, we found that HUVEC cell proliferation measured with CCK-8 and EdU assays (Figure 4B–D), migration measured with wound-healing assays (Figure 4E, F), and angiogenesis measured with tube-formation assays (Figure 4G, H) were all inhibited by the miR-23a-3p mimic and promoted by the miR-23a-3p inhibitor compared with the control cells. Collectively, these results indicated that upregulation and downregulation of miR-23a-3p inhibits and promotes, respectively, HUVEC proliferation, migration, and angiogenesis under hypoxia.

5. Identification of an MYU–miR-23a-3p–IL-8 axis that regulates angiogenesis under hypoxia

Having demonstrated that miR-23a-3p expression is negatively regulated by MYU, that IL-8 is negatively regulated by miR-23a-3p, and that IL-8 is positively regulated by MYU in HUVECs under hypoxia, we speculated that MYU may regulate angiogenesis by acting as a ceRNA for miR-23a-3p, thereby alleviating the repression of IL-8. To investigate this, we first employed RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid) and determined that IL-8 mRNA contains a potential binding site for miR-23a-3p in its 3′UTR region (Figure 5A). We next confirmed that miR-23a-3p could directly bind to IL-8 by using reporter assays. HUVECs were transfected with a miR-23a-3p mimic together with a luciferase reporter vector driven by either the IL-8-WT 3′UTR or an IL-8-MUT 3′UTR containing mutations in the putative miR-23a-3p binding site (Figure 5A). Notably, luciferase activity was significantly suppressed in cells co-expressing the miR-23a-3p mimic and the IL-8-WT reporter compared with the mimic plus IL-8-MUT reporter (p < 0.05, Figure 5B), demonstrating that miR-23a-3p directly binds to the 3′UTR of IL-8 mRNA.
Next, we examined the functional effects of concomitant modulation of the expression of both miR-23a-3p and MYU in HUVECs under hypoxia. HUVECs were co-transfected with an MYU overexpression plasmid plus miR-23a-3p mimic, NC, or miR-23a-3p inhibitor. Interestingly, qRT-PCR analysis of VEGF, HIF-1α, and IL-8 (Figure 5C) showed that IL-8 mRNA expression in MYU-overexpressing HUVECs was significantly reduced by co-transfection with the miR-23a-3p mimic (p < 0.05) and significantly increased by co-transfection with the miR-23a-3p inhibitor (p < 0.01). Interestingly, VEGFA mRNA levels were significantly downregulated upon co-transfer of MYU with miR-23a-3p inhibitors, in contrast to our expected results. Alternatively, the mRNA expression level of HIF-1α was not affected by co-transfection of MYU with miR-23a-3p (Figure 5C). Moreover, we observed the same pattern of effects of co-modulation of MYU and miR-23a-3p levels in the HUVEC functional assays. Thus, compared with MYU-overexpressing, NC-transfected HUVECs, MYU-overexpressing HUVECs transfected with the miR-23a-3p mimic or inhibitor exhibited elevated or suppressed, respectively, cell proliferation (p < 0.05, Figure 5D–F), cell migration (p < 0.05, Figure 5G, H), and tube formation and branching (p < 0.01, Figure 5I–K). Taken together, these results indicate that miR-23a-3p modulation counteracts the impact of MYU overexpression on HUVEC proliferation, migration, and angiogenesis under hypoxia.

Discussion

In this study, we investigated the biological functions of lncRNA MYU in HUVECs under hypoxic conditions. Our study was prompted by the demonstration that MYU promotes cancer cell survival during hypoxia. Yang et al.[31] examined the lncRNA expression profile of human CRC (Affymetrix Human Exon 1.0ST arrays) and identified MYU (VPS9D1-AS1) as a potential prognostic biomarker. MYU was also shown to be upregulated in cancer tissues compared adjacent normal tissues and was suggested to be a key regulator controlling CRC carcinogenesis and development. Wang et al.[33] found that MYU may promote the proliferation of prostate cancer cells by competitively binding to miR-184 and increasing the expression of c-Myc. Kawasaki et al.[30] demonstrated that MYU binds to hnRNP-K and stabilizes CDK6 expression, thereby promoting G1–S phase transition and playing a key role in the proliferation and tumorigenicity of colon cancer cells.
LncRNAs can regulate gene expression through various mechanisms, including chromatin remodeling, direct transcriptional regulation, and post-transcriptional processing [34,35,36]. LncRNAs that act as ceRNAs also play a major role in post-transcriptional regulation of protein-coding genes [35,36,37,38]. In the present study, we showed that MYU is upregulated in HUVECs during hypoxia, resulting in downregulation of miR-23a-3p. These data initially suggested an interaction between the two RNAs, and we then confirmed that MYU directly binds to miR-23a-3p to act as a molecular sponge, or ceRNA.
Several studies have demonstrated a crucial role for miR-23a-3p in hypoxia-related processes in cancer cells. For example, upregulation of miR-23a-3p is known to inhibit melanoma cell proliferation, migration, and invasion, and to promote apoptosis[39,40]. Wang et al.[41] showed that miR-23a-3p functions as a tumor suppressor in osteosarcoma, and its inhibitory effect was mainly mediated through downregulation of SATB1. Chen et al.[42] showed that miR-23a-3p may inhibit proliferation and invasion and promote apoptosis of oral squamous cell carcinoma cells by targeting FGF2. Wang et al.[43] revealed that miR-23a-3p inhibits endothelial progenitor cell activity in patients with coronary artery disease by targeting EGFR.
In addition, miR-23a-3p has an established role in angiogenesis. Kwok et al.[44] demonstrated that ginsenoside-Rg1 can induce angiogenesis and that miR-23a-3p negatively regulates MET tyrosine kinase receptor, indicating that miR-23a-3p can inhibit angiogenesis. Our results in the present study are consistent with those of Wu et al.[45], who showed that miR-23a-3p inhibited angiogenesis in HUVECs and zebrafish. However, a number of studies have also reported that miR-23a-3p can promote angiogenesis[46,47,48,49]. Zheng et al.[47] demonstrated that extracellular vesicles secreted by lung cancer cells can promote angiogenesis by transferring miR-23a-3p to HUVECs, resulting in reduced expression of the tumor suppressor PTEN and increased cell proliferation and migration. There are several potential explanations for these apparently conflicting results, including the use of different treatment conditions and cell types between studies. Further work will be necessary to clarify these observations.
A model summarizing our results is shown in Figure 6. Our findings are consistent with a scenario in which MYU promotes the upregulation of IL-8 in HUVECs under hypoxia by acting as a molecular sponge for miR-23a-3p, thereby preventing miR-23a-3p-mediated repression of IL-8 translation and leading to enhanced angiogenesis, proliferation, and migration. The MYU–miR-23a-3p–IL-8 regulatory axis provides a novel potential therapeutic target and lays the foundation for the development of new strategies for the treatment of diseases and conditions that involve abnormal vascular growth.
Authors’ contributions: Xiankun Zhou, Jiden Ma, and Jinwei Zhang designed the study. Xiankun Zhou, Mingxing Wen, and Jinwei Zhang contributed equally to this work. Xiankun Zhou drafted the manuscript and participated in all experiments. Liangpeng Ge, Jing Sun, and Mingxing Wen participated in most of the experiments during the revision stage. Xuewei Li and Mingzhou Li checked the writing format. Mingxing Wen and Jing Sun assisted with qPCR assays. Keren Long and Long Jin assisted in clinical data analysis. All authors have confirmed and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

All data presented or analyzed in this study are included either in this article.

Funding

This study has received funding from the National Natural Science Foundation of China (32072687 and 32302712); and Agricultural germplasm resources survey, collection, protection, and identification service project of the Ministry of Agriculture and Rural Affairs (A120202); and the Major Science and Technology Projects of Tibet Autonomous Region (XZ202101ZD0005N).

Acknowledgements

We thank Anne M. O’Rourke, PhD, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Conflicts of Interest

The authors declare that they have no competing interests.

Abbreviations

BLCA
Bladder Urothelial Carcinoma;
BRCA
Breast invasive carcinoma;
CESC
Cervical squamous cell carcinoma and endocervical adenocarcinoma;
COAD
Colon adenocarcinoma;
ESCA
Esophageal carcinoma;
HNSC
Head and Neck squamous cell carcinoma;
KIRC
Kidney renal clear cell carcinoma;
LGG
Brain Lower Grade Glioma;
LIHC
Liver hepatocellular carcinoma;
LUAD
Lung adenocarcinoma;
LUSC
Lung squamous cell carcinoma;
MESO
Mesothelioma;
OV
Ovarian serous cystadenocarcinoma;
PAAD
Pancreatic adenocarcinoma;
PRAD
Prostate adenocarcinoma;
READ
Rectum adenocarcinoma;
SARC
Sarcoma;
SKCM
Skin Cutaneous Melanoma;
STAD
Stomach adenocarcinoma;
TGCT
Testicular Germ Cell Tumors;
THCA
Thyroid carcinoma;
UCEC
Uterine Corpus Endometrial Carcinoma.

References

  1. Zhao X, Nedvetsky P, Stanchi F, et al. Endothelial PKA activity regulates angiogenesis by limiting autophagy through phosphorylation of ATG16L1. Elife, 2019, 8, e46380. [Google Scholar] [CrossRef] [PubMed]
  2. Liang X, Zhang L, Wang S, et al. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J Cell Sci, 2016, 129, 2182–2189. [Google Scholar] [CrossRef] [PubMed]
  3. 3. Tetzlaff F, Adam MG, Feldner A, et al. MPDZ promotes DLL4-induced Notch signaling during angiogenesis. Elife.
  4. Bower NI, Vogrin AJ, Le Guen L, et al. Vegfd modulates both angiogenesis and lymphangiogenesis during zebrafish embryonic development. Development, 2017, 144, 507–518. [Google Scholar] [CrossRef] [PubMed]
  5. Demir R, Yaba A, Huppertz B. Vasculogenesis and angiogenesis in the endometrium during menstrual cycle and implantation. Acta Histochem, 2010, 112, 203–214. [Google Scholar] [CrossRef] [PubMed]
  6. Chen DB, Zheng J. Regulation of placental angiogenesis. Microcirculation, 2014, 21, 15–25. [Google Scholar] [CrossRef] [PubMed]
  7. Zaniolo K, Sapieha P, Shao Z, et al. Ghrelin modulates physiologic and pathologic retinal angiogenesis through GHSR-1a. Invest Ophthalmol Visual Sci, 2011, 52, 5376–5386. [Google Scholar] [CrossRef] [PubMed]
  8. Bodnar, RJ. Chemokine regulation of angiogenesis during wound healing. Adv Wound Care, 2015, 4, 641–650. [Google Scholar] [CrossRef] [PubMed]
  9. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med, 2011, 17, 1359–1370. [Google Scholar] [CrossRef]
  10. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer, 2010, 102, 8–18. [Google Scholar] [CrossRef]
  11. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett, 2013, 328, 18–26. [Google Scholar] [CrossRef]
  12. Bono F, De Smet F, Herbert C, et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell, 2013, 23, 477–488. [Google Scholar] [CrossRef]
  13. Assadian S, El-Assaad W, Wang XQ, et al. p53 inhibits angiogenesis by inducing the production of Arresten. Cancer Res, 2012, 72, 1270–1279. [Google Scholar] [CrossRef]
  14. Wang H, Chen Y, Lu X-A, et al. Endostatin prevents dietary-induced obesity by inhibiting adipogenesis and angiogenesis. Diabetes, 2015, 64, 2442–2456. [Google Scholar] [CrossRef] [PubMed]
  15. Almeida I, Oliveira GA, Lima M, et al. Different contributions of angiostatin and endostatin in angiogenesis impairment in systemic sclerosis: a cohort study. Clin Exp Rheumatol, 2016, 34, 37. [Google Scholar]
  16. Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation-and metastasis-sustaining neovasculature. Matrix Biol, 2015, 44, 94–112. [Google Scholar]
  17. Soufi-Zomorrod M, Hajifathali A, Kouhkan F, et al. MicroRNAs modulating angiogenesis: miR-129-1 and miR-133 act as angio-miR in HUVECs. Tumor Biol, 2016, 37, 9527–9534. [Google Scholar] [CrossRef] [PubMed]
  18. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell, 2011, 43, 904–914. [Google Scholar] [CrossRef]
  19. Voellenkle C, Garcia-Manteiga JM, Pedrotti S, et al. Implication of Long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing. Sci Rep, 2016, 6, 24141. [Google Scholar] [CrossRef]
  20. Zhang Z-C, Tang C, Dong Y, et al. Targeting the long noncoding RNA MALAT1 blocks the pro-angiogenic effects of osteosarcoma and suppresses tumour growth. Int J Biol Sci, 2017, 13, 1398. [Google Scholar]
  21. Neumann P, Jaé N, Knau A, et al. The lncRNA GATA6-AS epigenetically regulates endothelial gene expression via interaction with LOXL2. Nature communications, 2018, 9, 1–12. [Google Scholar]
  22. Choudhry H, Harris AL, Mcintyre A. The tumour hypoxia induced non-coding transcriptome. Mol Aspects Med, 2016, 47, 35–53. [Google Scholar]
  23. Liu J, Li Q, Zhang K-S, et al. Downregulation of the long non-coding RNA Meg3 promotes angiogenesis after ischemic brain injury by activating notch signaling. Mol Neurobiol, 2017, 54, 8179–8190. [Google Scholar] [CrossRef] [PubMed]
  24. Li L, Wang M, Mei Z, et al. lncRNAs HIF1A-AS2 facilitates the up-regulation of HIF-1α by sponging to miR-153-3p, whereby promoting angiogenesis in HUVECs in hypoxia. Biomed Pharmacother, 2017, 96, 165–172. [Google Scholar] [CrossRef] [PubMed]
  25. Yin D, Fu C, Sun D. Silence of lncRNA UCA1 represses the growth and tube formation of human microvascular endothelial cells through miR-195. Cell Physiol Biochem, 2018, 49, 1499–1511. [Google Scholar] [CrossRef] [PubMed]
  26. Zhou Z-W, Zheng L-J, Ren X, et al. LncRNA NEAT1 facilitates survival and angiogenesis in oxygen-glucose deprivation (OGD)-induced brain microvascular endothelial cells (BMECs) via targeting miR-377 and upregulating SIRT1, VEGFA, and BCL-XL. Brain Res, 2019, 1707, 90–98. [Google Scholar] [CrossRef] [PubMed]
  27. Sun Y, Xiong X, Wang X. RELA promotes hypoxia-induced angiogenesis in human umbilical vascular endothelial cells via LINC01693/miR-302d/CXCL12 axis. J Cell Biochem, 2019, 120, 12549–12558. [Google Scholar] [CrossRef]
  28. Ma Y, Wang P, Xue Y, et al. PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186. Tumor Biol, 2017, 39, 1010428317694326. [Google Scholar]
  29. He C, Yang W, Yang J, et al. Long noncoding RNA MEG3 negatively regulates proliferation and angiogenesis in vascular endothelial cells. DNA Cell Biol, 2017, 36, 475–481. [Google Scholar] [CrossRef]
  30. Kawasaki Y, Komiya M, Matsumura K, et al. MYU, a target lncRNA for Wnt/c-Myc signaling, mediates induction of CDK6 to promote cell cycle progression. Cell Rep, 2016, 16, 2554–2564. [Google Scholar] [CrossRef]
  31. Yang L, Xu L, Wang Q, et al. Dysregulation of long non-coding RNA profiles in human colorectal cancer and its association with overall survival. Oncol Lett, 2016, 12, 4068–4074. [Google Scholar] [CrossRef]
  32. Moreau PR, Örd T, Downes NL, et al. Transcriptional profiling of hypoxia-regulated non-coding RNAs in human primary endothelial cells. Frontiers in Cardiovascular Medicine, 2018, 5, 159. [Google Scholar] [CrossRef] [PubMed]
  33. Wang J, Yang X, Li R, et al. Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis. Oncol Rep, 2018, 40, 2814–2825. [Google Scholar]
  34. Zhang X, Li H, Burnett JC, et al. The role of antisense long noncoding RNA in small RNA-triggered gene activation. RNA, 2014, 20, 1916–1928. [Google Scholar] [CrossRef]
  35. Ge Y, Yan X, Jin Y, et al. fMiRNA-192 and miRNA-204 directly suppress lncRNA HOTTIP and interrupt GLS1-mediated glutaminolysis in hepatocellular carcinoma. PLoS Genet, 2015, 11, e1005726. [Google Scholar]
  36. Chen Z-H, Wang W-T, Huang W, et al. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ, 2017, 24, 212–224. [Google Scholar] [CrossRef] [PubMed]
  37. Parolia A, Crea F, Xue H, et al. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Mol Cancer, 2015, 14, 1–7. [Google Scholar]
  38. Liu X-H, Sun M, Nie F-Q, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer, 2014, 13, 92. [Google Scholar] [CrossRef] [PubMed]
  39. Wang P, Hu L, Fu G, et al. LncRNA MALAT1 Promotes the Proliferation, Migration, and Invasion of Melanoma Cells by Downregulating miR-23a. Cancer Manag Res, 2020, 12, 6553. [Google Scholar] [CrossRef] [PubMed]
  40. Lu S, Xu Q. MicroRNA-23a inhibits melanoma cell proliferation, migration, and invasion in mice through a negative feedback regulation of sdcbp and the MAPK/ERK signaling pathway. IUBMB Life, 2019, 71, 587–600. [Google Scholar] [CrossRef]
  41. Wang G, Li B, Fu Y, et al. miR-23a suppresses proliferation of osteosarcoma cells by targeting SATB1. Tumor Biol, 2015, 36, 4715–4721. [Google Scholar] [CrossRef]
  42. Chen F, Qi S, Zhang X, et al. miR-23a-3p suppresses cell proliferation in oral squamous cell carcinomas by targeting FGF2 and correlates with a better prognosis: miR-23a-3p inhibits OSCC growth by targeting FGF2. Pathology-Research and Practice, 2019, 215, 660–667. [Google Scholar] [CrossRef] [PubMed]
  43. Wang S, He W, Wang C. MiR-23a Regulates the Vasculogenesis of Coronary Artery Disease by Targeting Epidermal Growth Factor Receptor. Cardiovasc Ther, 2016, 34, 199–208. [Google Scholar] [CrossRef] [PubMed]
  44. Kwok H-H, Chan L-S, Poon P-Y, et al. Ginsenoside-Rg1 induces angiogenesis by the inverse regulation of MET tyrosine kinase receptor expression through miR-23a. Toxicol Appl Pharmacol, 2015, 287, 276–283. [Google Scholar] [CrossRef] [PubMed]
  45. Wu X-D, Guo T, Liu L, et al. MiR-23a targets RUNX2 and suppresses ginsenoside Rg1-induced angiogenesis in endothelial cells. Oncotarget, 2017, 8, 58072. [Google Scholar] [CrossRef] [PubMed]
  46. Sruthi T, Edatt L, Raji GR, et al. Horizontal transfer of miR-23a from hypoxic tumor cell colonies can induce angiogenesis. J Cell Physiol, 2018, 233, 3498–3514. [Google Scholar] [CrossRef]
  47. Zheng Y, Liu L, Chen C, et al. The extracellular vesicles secreted by lung cancer cells in radiation therapy promote endothelial cell angiogenesis by transferring miR-23a. PeerJ, 2017, 5, e3627. [Google Scholar] [CrossRef] [PubMed]
  48. Hsu Y, Hung J, Chang W, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene, 2017, 36, 4929–4942. [Google Scholar] [CrossRef]
  49. Bao L, You B, Shi S, et al. Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10. Oncogene, 2018, 37, 2873–2889. [Google Scholar] [CrossRef]
Preprints 109775 g001
Figure 1. Expression pattern of MYU. (A) MYU expression levels in various tumor types and corresponding normal tissues in TCGA datasets. The corresponding Heatmap represents the average expression of MYU genes in each kind cancer tissue. (B) Genomic landscape of MYU using the UCSC Genome Browser. The chromosomal location of MYU and examples of its conservation in vertebrates are shown. (C) In vitro translation experiments show no evidence of protein production by MYU. (D) Trypan blue staining of nuclei isolated from HUVECs. (E) qRT-PCR analysis of MYU in the nuclear and cytoplasmic fractions of HUVECs. (F) qRT-PCR analysis of MYU in HUVECs cultured under hypoxic or normoxic conditions for various times. All experiments except (F) were conducted under normoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Figure 1. Expression pattern of MYU. (A) MYU expression levels in various tumor types and corresponding normal tissues in TCGA datasets. The corresponding Heatmap represents the average expression of MYU genes in each kind cancer tissue. (B) Genomic landscape of MYU using the UCSC Genome Browser. The chromosomal location of MYU and examples of its conservation in vertebrates are shown. (C) In vitro translation experiments show no evidence of protein production by MYU. (D) Trypan blue staining of nuclei isolated from HUVECs. (E) qRT-PCR analysis of MYU in the nuclear and cytoplasmic fractions of HUVECs. (F) qRT-PCR analysis of MYU in HUVECs cultured under hypoxic or normoxic conditions for various times. All experiments except (F) were conducted under normoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Preprints 109775 g001
Preprints 109775 g002
Figure 2. MYU is required for HUVEC proliferation, migration, and angiogenesis. (A and B) qRT-PCR analysis of MYU (A), IL-8, VEGFA, and HIF-1α (B) in HUVECs transfected with empty vector or an MYU expression vector. (C–E) Cell proliferation of control and MYU-overexpressing HUVECs detected with CCK-8 (C) and EdU (D and E) assays. Scale bar: 100 μm. (F and G) Images (F) and quantification (G) of migration of control or MYU-overexpressing HUVECs. Wound-healing assays were performed in serum-free medium. Scale bar: 100 μm. (H–J) Images (H) and quantification of branching (I) and tube length (J) by control or MYU-overexpressing HUVECs cultured in Matrigel-coated wells. Scale bar: 100 μm. All experiments were conducted under hypoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Figure 2. MYU is required for HUVEC proliferation, migration, and angiogenesis. (A and B) qRT-PCR analysis of MYU (A), IL-8, VEGFA, and HIF-1α (B) in HUVECs transfected with empty vector or an MYU expression vector. (C–E) Cell proliferation of control and MYU-overexpressing HUVECs detected with CCK-8 (C) and EdU (D and E) assays. Scale bar: 100 μm. (F and G) Images (F) and quantification (G) of migration of control or MYU-overexpressing HUVECs. Wound-healing assays were performed in serum-free medium. Scale bar: 100 μm. (H–J) Images (H) and quantification of branching (I) and tube length (J) by control or MYU-overexpressing HUVECs cultured in Matrigel-coated wells. Scale bar: 100 μm. All experiments were conducted under hypoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Preprints 109775 g002
Preprints 109775 g003
Figure 3. Interaction between MYU and miR-23a-3p in HUVECs. (A) Sequences of potential binding sites between MYU and miR-23a-3p predicted by RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid) and luciferase reporter constructs showing the location of the putative miR-23a-3p binding site in the wild-type (MYU-WT) and mutated (MYU-MUT) sequences in pmirGLO vector. (B) qRT-PCR analysis of miR-23a-3p levels in HUVECs transfected with a control or MYU overexpression vector. (C) Relative luciferase activity in HUVECs co-transfected with pmirGLO containing either the WT-MUT or MUT-MYU vectors and a miR-23a-3p mimic. Fig. B experiments were conducted under hypoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Figure 3. Interaction between MYU and miR-23a-3p in HUVECs. (A) Sequences of potential binding sites between MYU and miR-23a-3p predicted by RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid) and luciferase reporter constructs showing the location of the putative miR-23a-3p binding site in the wild-type (MYU-WT) and mutated (MYU-MUT) sequences in pmirGLO vector. (B) qRT-PCR analysis of miR-23a-3p levels in HUVECs transfected with a control or MYU overexpression vector. (C) Relative luciferase activity in HUVECs co-transfected with pmirGLO containing either the WT-MUT or MUT-MYU vectors and a miR-23a-3p mimic. Fig. B experiments were conducted under hypoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Preprints 109775 g003
Preprints 109775 g004
Figure 4. miR-23a-3p is required for HUVEC proliferation, migration, and angiogenesis under hypoxia. (A) qRT-PCR analysis of IL-8, VEGFA, and HIF-1α mRNA in HUVECs transfected with a control sequence (NC), a miR-23a-3p mimic, or a miR-23a-3p inhibitor. (B–D) HUVEC cell proliferation detected using CCK-8 (B) and EdU (C, D) assays. Scale bar: 100 μm. (E and F) Migration of HUVECs in wound-healing assays performed in serum-free medium. Scale bar: 100 μm. (G–I) Tube-formation and branching of HUVECs in Matrigel-coated wells. Scale bar: 100 μm. All experiments were conducted under hypoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Figure 4. miR-23a-3p is required for HUVEC proliferation, migration, and angiogenesis under hypoxia. (A) qRT-PCR analysis of IL-8, VEGFA, and HIF-1α mRNA in HUVECs transfected with a control sequence (NC), a miR-23a-3p mimic, or a miR-23a-3p inhibitor. (B–D) HUVEC cell proliferation detected using CCK-8 (B) and EdU (C, D) assays. Scale bar: 100 μm. (E and F) Migration of HUVECs in wound-healing assays performed in serum-free medium. Scale bar: 100 μm. (G–I) Tube-formation and branching of HUVECs in Matrigel-coated wells. Scale bar: 100 μm. All experiments were conducted under hypoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Preprints 109775 g004
Preprints 109775 g005aPreprints 109775 g005b
Figure 5. The MYU–miR-23a-3p–IL-8 axis regulates angiogenesis under hypoxia. (A) The potential binding site sequences between IL8 3 'UTR and miR-23a-3p predicted by RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid) and luciferase reporter constructs showing the location of the putative miR-23a-3p binding site in the wild-type and mutated IL-8 3′UTR. (B) Relative luciferase activity in HUVECs co-transfected with pmirGLO vectors and miR-23a-3p mimic. (C) qRT-PCR analysis of IL-8, VEGFA, and HIF-1α mRNA levels in HUVECs co-transfected with an MYU overexpression vector and miR-23a-3p mimic, miR-23a-3p inhibitor, or negative control (NC) sequence. (D–F) HUVEC cell proliferation detected using CCK-8 (D) and EdU (E and F) assays. Scale bar: 100 μm. (G and H) Migration of HUVECs in wound-healing assays performed in serum-free medium. Scale bar: 100 μm. (I–K) Tube-formation and branching of HUVECs in Matrigel-coated wells. Scale bar: 100 μm. Fig. C–K experiments were conducted under hypoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Figure 5. The MYU–miR-23a-3p–IL-8 axis regulates angiogenesis under hypoxia. (A) The potential binding site sequences between IL8 3 'UTR and miR-23a-3p predicted by RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid) and luciferase reporter constructs showing the location of the putative miR-23a-3p binding site in the wild-type and mutated IL-8 3′UTR. (B) Relative luciferase activity in HUVECs co-transfected with pmirGLO vectors and miR-23a-3p mimic. (C) qRT-PCR analysis of IL-8, VEGFA, and HIF-1α mRNA levels in HUVECs co-transfected with an MYU overexpression vector and miR-23a-3p mimic, miR-23a-3p inhibitor, or negative control (NC) sequence. (D–F) HUVEC cell proliferation detected using CCK-8 (D) and EdU (E and F) assays. Scale bar: 100 μm. (G and H) Migration of HUVECs in wound-healing assays performed in serum-free medium. Scale bar: 100 μm. (I–K) Tube-formation and branching of HUVECs in Matrigel-coated wells. Scale bar: 100 μm. Fig. C–K experiments were conducted under hypoxic conditions. Data represent the mean ± SD (n = 3). * p < 0.05, ** p < 0.01, ns = not significant.
Preprints 109775 g005aPreprints 109775 g005b
Preprints 109775 g006
Figure 6. Model for the regulation of angiogenesis by the MYU–miR-23a-3p–IL-8 axis in HUVECs under hypoxia.
Figure 6. Model for the regulation of angiogenesis by the MYU–miR-23a-3p–IL-8 axis in HUVECs under hypoxia.
Preprints 109775 g006
Table 1. Primer Sequences for qRT-PCR.
Table 1. Primer Sequences for qRT-PCR.
Gene Accession No. Primers Sequence
MYU ENST00000562866.1 F 5’ ATGGGTAACCAGGGGTCAAG 3’
R 5’ AGTAACAGTGGTAGAGCCGAC 3’
IL8 ENST00000307407.8 F 5’ ACTGAGAGTGATTGAGAGTGGAC 3’
R 5’ AACCCTCTGCACCCAGTTTTC 3’
HIF1α ENST00000539097.2 F 5’ TCCAAGAAGCCCTAACGTGT 3’
R 5’ TGATCGTCTGGCTGCTGTAA 3’
VEGF-A ENST00000372067.7 F 5’ ATGCGGATCAAACCTCACCA 3’
R 5’ CACCAACGTACACGCTCCAG 3’
GAPDH ENST00000396861.5 F 5’ GGAGCGAGATCCCTCCAAAAT 3’
R 5’ GGCTGTTGTCATACTTCTCATGGA 3’
U6 NR_004394.1 F 5’ CTCGCTTCGGCAGCACA 3’
R 5’ AACGCTTCACGAATTTGCGT 3’
hsa-miR-23a-3p MIMAT0000078 F 5’ ATCACATTGCCAGGGATTTCC 3’
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
bsky
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated